BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer
Pilot Feasibility Study of Intratumoral BO-112 in Combination With Pembrolizumab for Advanced Hepatocellular Carcinoma
Sponsor: Highlight Therapeutics
Terminated
Withdrawn by sponsor
Other terminated trials from Highlight Therapeutics
More terminations from Highlight Therapeutics
Other Advanced Hepatocellular Carcinoma trials with similar outcome
A EARLY_PHASE1 clinical study on Advanced Hepatocellular Carcinoma and BCLC Stage B Hepatocellular Carcinoma, this trial is terminated or withdrawn. The trial is conducted by Highlight Therapeutics and has accumulated 10 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated EARLY_PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated EARLY_PHASE1
-
Apr 2023 — Jul 2024 [monthly]
Terminated EARLY_PHASE1
Status: Suspended → Terminated
-
Jan 2023 — Apr 2023 [monthly]
Suspended EARLY_PHASE1
Status: Recruiting → Suspended
-
Jun 2022 — Jan 2023 [monthly]
Recruiting EARLY_PHASE1
▶ Show 5 earlier versions
-
Dec 2021 — Jun 2022 [monthly]
Recruiting EARLY_PHASE1
Status: Not Yet Recruiting → Recruiting
-
Oct 2021 — Dec 2021 [monthly]
Not Yet Recruiting EARLY_PHASE1
-
Sep 2021 — Oct 2021 [monthly]
Not Yet Recruiting EARLY_PHASE1
-
Jun 2021 — Sep 2021 [monthly]
Not Yet Recruiting EARLY_PHASE1
-
Apr 2021 — Jun 2021 [monthly]
Not Yet Recruiting EARLY_PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Highlight Therapeutics
- Jonsson Comprehensive Cancer Center
- Merck Sharp & Dohme LLC
For direct contact, visit the study record on ClinicalTrials.gov .